RDY : Summary for Dr. Reddy's Laboratories Ltd Co - Yahoo Finance

U.S. Markets closed

Dr. Reddy's Laboratories Limited (RDY)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
43.47-0.12 (-0.28%)
At close: 4:02PM EST
People also watch
HDBWITIBNTTMINFY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close43.59
Open43.44
Bid0.00 x
Ask0.00 x
Day's Range43.16 - 43.55
52 Week Range41.60 - 54.73
Volume210,084
Avg. Volume287,042
Market Cap7.14B
Beta0.24
PE Ratio (TTM)51.87
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.30 (0.69%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire12 days ago

    Dr. Reddy's Expands Commercial Operations in Europe

    BASEL, Switzerland, February 8, 2017 /PRNewswire/ -- Dr. Reddy's Laboratories Ltd  announced today the expansion of its commercial operations in Europe with the introduction of its portfolio of generics ...

  • American City Business Journals12 days ago

    BioMarin sues to stop generic version of its $90K-a-year drug

    Rare-disease drug developer BioMarin Pharmaceutical Inc. sued an Indian drug maker that plans to make and sell a version of one of BioMarin's top-selling drugs. The San Rafael company (BMRN), led by CEO Jean-Jacques Bienaimé, said in a filing Monday in U.S. District Court in New Jersey that a version of the drug Kuvan by Dr. Reddy's Laboratories Ltd. infringes on six BioMarin patents. The Indian company late last year asked the Food and Drug Administration to approve its powder version of Kuvan, saying that BioMarin's patents are invalid, unenforceable or will not be infringed by manufacturing, use or sale.

  • Dr. Reddy’s Laboratories Ltd. :RDY-US: Earnings Analysis: Q3, 2017 By the Numbers : February 7, 2017
    Capital Cube13 days ago

    Dr. Reddy’s Laboratories Ltd. :RDY-US: Earnings Analysis: Q3, 2017 By the Numbers : February 7, 2017

    Categories: Yahoo Finance Get free summary analysis Dr. Reddy’s Laboratories Ltd. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Dr. Reddy’s Laboratories Ltd. – Pfizer Inc., Novartis AG Sponsored ADR and Wockhardt Limited Sponsored GDR (PFE-US, NVS-US and WKHZF-US) that have also reported for this period. ... Read more (Read more...)